Search

A recent U.S. Supreme Court opinion in favor of the Food and Drug Administration in an e-cigarette case has implications for drugs and other medical products regulated by the agency, according to a Pink Sheet article by McGuireWoods’ Craig Bleifer, Royce DuBiner, Max Bogost, Michael Brody and Allyson Maur. In FDA v. Wages and White Lion Investments, the high court unanimously reversed a ruling by the U.S. Court of Appeals for the …

McGuireWoods advised vVARDIS, a Swiss high-growth dental company, in a $35 million financing with OrbiMed, a leading healthcare investment firm. The capital will support vVARDIS’ growth initiatives and global commercial expansion. vVARDIS is a developer and manufacturer of non-invasive dental products under the Curodont brand. Thousands of dental clinics in the United States and European Union employ vVARDIS products in their practices, which also are incorporated in lectures at renowned universities in the …

… company in its initial public offering and several other securities offerings, as well as the acquisition of dermatology company Cutanea Life Sciences. The firm also advised Biofrontera on U.S. securities law and regulatory issues and litigation matters. Additional recent transactions include: Representing SinglePoint, a diversified holding company principally engaged through its subsidiaries in providing renewable energy solutions and energy-efficient applications, in a Regulation A offering of up to $75 million. The deal …

The use of artificial intelligence and machine learning (AI/ML) in healthcare may improve patient care and health outcomes but also brings risks that should worry providers, McGuireWoods associates Allyson Maur and Micaela Enger wrote in the November 2024 edition of Chicago Medicine. Maur and Enger cited implicit and explicit bias in the data used to train AI/ML models, patient privacy risks, and an overreliance on AI/ML in making clinical decisions as serious …